Moreover, while we imply the superiority of immunotherapy over chemotherapy in melanoma treatment, it is important to recognize that the chemotherapy group consists of BRAF/MEK inhibitors, which may be the first‐line treatment in select melanoma cases. This evidence concerns the gene MAP2K7 and melanoma.